Three Rivers Pharmaceuticals, a privately held company that focuses on specialized therapies including hepatitis C therapies, has signed a definitive licensing agreement with Amgen to expand its commercial rights to the hepatitis C drug Infergen.
Three Rivers Pharmaceuticals will obtain commercial rights to Infergen in all markets except Japan. In addition, Three Rivers Pharmaceuticals will obtain commercial rights to China, effective March 31, 2009. Three Rivers Pharmaceuticals currently has commercial rights to Infergen in the US and Canada.
Three Rivers Pharmaceuticals will seek marketing partners to assist with the commercialization of Infergen outside of the US.
Infergen is indicated for the treatment of chronic hepatitis C virus (HCV)infection in patients 18 years of age or older with compensated liver disease who have anti-HCV serum antibodies or the presence of HCV RNA.
Patrick Kerrish, executive vice president of business development at Three Rivers Pharmaceuticals, said: “The expansion of commercial rights to Infergen compliments Three Rivers Pharmaceuticals strategy to continue to grow its hepatitis C franchise.”
Comments